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The genetic concept of synthetic lethality has now been validated clinically through the 
demonstrated efficacy of PARP inhibitors (PARPi) for the treatment of cancers in individuals with 
germline mutations in either BRCA1 or BRCA2. Three different PARPi have now been approved 
for the treatment of BRCA-mutated ovarian cancer and one for BRCA-mutated breast cancer; 
these agents have also shown promising results in BRCA-mutated prostate cancer. Here we 
describe a number of other synthetic lethal interactions that have been discovered in human 
cancer. We will discuss some of the underlying principles that may enhance the likelihood of 
clinical efficacy and how new computational and experimental approaches are facilitating the 
discovery and validation of additional synthetic lethal interactions. Finally, we will make 
suggestions as to future directions and challenges facing this field.  
 
(Main text 6500 words, 113 references) 
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1. Introduction  
 
Synthetic lethality is a concept introduced almost 100 years ago by the fly geneticist Calvin 
Bridges1 and named by Theodor Dobzhansky in 19462. It describes the situation in a cell or 
organism whereby a defect in either one of two genes has little or no effect, but the combination 
of both gene defects results in sickness (synthetic sickness) or death (synthetic lethality)3. This 
concept had been long-studied by geneticists and developmental biologists but it was an article 
by Hartwell and colleagues4, and subsequently highlighted by Kaelin5, Brummelkamp, Bernards6, 
and others, which fuelled interest in using the synthetic lethal concept to develop cancer 
therapeutics. synthetic lethal interactions are a form of context dependent essentiality7, where a 
genetic alteration, such as a defect in a tumor suppressor gene (the context), causes a second 
gene to become essential for cell survival; drug inhibition of this second, synthetic lethal gene 
would in principle target tumour cells, but leave normal cells largely unaffected. As well as 
providing an approach that can be used to selectively target tumor cells and spare normal cells, 
application of the synthetic lethal principle also raises the prospect of precisely targeting 
subgroups of cancer that are defined by a known molecular change such as a driver mutation. As 
our understanding of the genetic alterations in cancer has developed, the synthetic lethal concept 
has been expanded to include a number of other related genetic concepts such as induced 
essentiality8 and collateral sensitivity9,10 (discussed below) and synthetic dosage lethality (SDL), 
a term that defines the situation when elevated activity of a gene (as opposed to loss) renders 
another gene essential. 
 
The Poly(ADP-ribose) Polymerase 1 and 2 (PARP1 and PARP2) enzymes are important DNA 
damage sensors and signal transducers in the DNA Damage Response (DDR) that bind single 
strand DNA breaks (SSBs) and other types of DNA damage. Upon binding DNA, PARP1 and 
PARP2 post-translationally modify substrate proteins by synthesising poly(ADP-ribose) (PAR) 
chains (PARylation). Significant effort over many years has led to the discovery and development 
of small molecule inhibitors of PARP (PARPi), some of which have entered the clinic11. In 2005, 
two groups12,13 discovered a synthetic lethal interaction between inhibition of PARP and BRCA1 
or BRCA2 gene mutation.  
 
BRCA1 and BRCA2 are tumor suppressor genes that when heterozygously mutated in the 
germline confer considerably higher risks of several cancers including breast, ovarian, pancreatic 
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and prostate. BRCA1 and BRCA2 proteins are crucial to the repair of double strand DNA breaks 
by homologous recombination (HR)11. Tumors harbor loss of the wild-type BRCA allele and 
therefore carry a defect in HR. The synthetic lethal interaction between PARPi and loss of BRCA 
function is thought to be related to increased number of double strand DNA breaks or collapsed 
replication forks induced by PARP enzyme inhibition or trapping on DNA. Importantly, the 
magnitude of the synthetic lethal effect in laboratory models of BRCA mutation was substantial, 
an observation which encouraged early translation into clinic trials11. 
 
Initial observations in phase 1/1b and then phase 2 clinical trials demonstrated initial proof of 
concept of the validity of the approach, with multiple BRCA mutant cancer patients exhibiting 
profound and sustained responses to the PARPi olaparib (KuDOS/AstraZeneca)14-16. Subsequent 
trials confirmed these results and the United States Food and Drug Administration (FDA) has now 
approved three PARPi for clinical use: olaparib, rucaparib (Pfizer/Clovis) and niraparib 
(Merck/Tesaro) for BRCA-mutated ovarian cancer11. Olaparib has also now been approved by 
the FDA for the treatment of BRCA-mutated breast cancer (Table 1).  
 
Although responses to PARPi in the BRCA-mutant group were profound enough to gain FDA 
approval, both de novo and acquired resistance to PARPi therapy is common. A number of 
mechanisms to explain this have been proposed, most of which center on the restoration of HR 
in tumor cells, either directly through reversion mutations in BRCA1 or BRCA2, or indirectly via 
alterations in other components of the DDR17. It appears that, in common with other targeted 
therapies, PARPi treatment also results in Darwinian selection, favoring the survival and 
proliferation of tumor cell clones with BRCA gene reversion mutations above those that do not18. 
Considerable effort is now being directed at improving responses to PARPi, either through PARPi 
combination strategies19 or through alternative targets in the BRCA-mutant tumor cells (see 
below).  
 
The discovery and development of the first clinically approved synthetic lethal cancer therapy has 
fostered interest in the potential for exploiting other synthetic lethal interactions. In this review, 
illustrative recent examples of synthetic lethal interactions in diverse cellular pathways will be 
discussed with an emphasis on those that may eventually be clinically actionable. In addition, new 
technologies that may shape the discovery of additional synthetic lethal interactions will be 
described. Finally, new directions for the field will be suggested. 
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2. Synthetic Lethal Interactions by Cellular Pathway  
 
(i) The DNA Damage Response Pathway (DDR)  
 
The DDR is a set of highly connected molecular networks that maintain genomic integrity, thus 
preventing the transmission of altered genetic material to daughter cells and acting as a tumor 
suppressive barrier. For decades, gene perturbation studies in yeast have catalogued synthetic 
lethal interactions associated with genes involved in the DDR (for example20,21). One common 
feature of these studies has been the identification of multiple synthetic lethal interactions 
between pairs of DDR genes, an observation that likely reflects how multiple molecular processes 
interact to prevent the formation of what might be otherwise cytotoxic or fitness-impairing DNA 
lesions. The search for synthetic lethal interactions within the DDR has focussed largely on 
identifying: (a) additional synthetic lethal uses for PARPi; (b) alternative ways of synthetic lethal 
targeting BRCA mutant tumors that might supersede PARPi or overcome PARPi resistance; and 
(c) the targeting of non-BRCA and PARP related DDR synthetic lethal effects in tumors.  
 
Additional synthetic lethal uses for PARPi. BRCAness is a term used to define a subset of 
tumors that lack germline BRCA gene mutations but share similar characteristics, in particular a 
defect in HR. As such they are phenocopies of germline BRCA mutant tumors22. Because of the 
defect in HR it might be expected that tumors with BRCAness might also show an synthetic lethal 
interaction with PARPi. In some respects, this has proved the case; defects in one of a number 
of tumor suppressor genes involved in HR and/or associated DNA repair pathways such as ATM, 
ATR, and PALB2, also cause sensitivity to PARPi in pre-clinical models22,23. Genetic screens have 
revealed additional genes defective in cancer, such as CDK12, RAD51B and RAD51C, that may 
also confer BRCAness20. Widespread sequencing of human tumors has revealed that significant 
proportions of high-grade serous ovarian cancers, advanced, castration-resistant, prostate 
cancer, pancreatic cancer and others harbor mutations in genes that could be classified as 
conferring BRCAness22,24-26. In addition, it seems possible that a combination of genetic, genomic 
and/or epigenetic defects in a single tumor cell could also cause an HR defect and BRCAness; 
however, the precise nature of these complex causes of BRCAness are still under investigation, 
as is their ability to predict significant clinical sensitivity to PARPi22.  
 
Alternative ways of synthetic lethal targeting BRCA mutant tumors. Given that resistance to 
PARPi is clinically important in BRCA mutant tumors there has been considerable effort in 
identifying additional BRCA synthetic lethal interactions that might either be superior to PARPi in 
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terms of therapeutic effect or that may overcome PARPi resistance. Two groups27,28 have 
produced data suggesting that the low-fidelity DNA polymerase theta (Pol theta, encoded by the 
POLQ gene) may be a synthetic lethal target for the treatment of BRCA1 mutated cancers. Pol 
theta is involved in a form of double strand DNA repair, known as microhomology-mediated end 
joining (MMEJ); this error-prone pathway requires PARP1. Because the survival of BRCA1-
deficient cancer cells appears dependent on MMEJ, inhibition of Pol theta induces synthetic lethal. 
In part, this might be because Pol theta normally acts to inhibit HR (perhaps by sequestration of 
the DNA recombinase and BRCA2 interacting protein, RAD51) and therefore there may be an 
increased reliance on HR. In addition, silencing of Pol theta enhances the effects of PARPi or 
DNA cross-linking agents in HR-deficient ovarian cancer cells23,24. As a result of these studies, a 
number of companies are developing Pol theta inhibitors. The appropriate clinical context for the 
use of these agents, either superseding PARPi, used in combination with PARPi or used after 
PARPi resistance has emerged, remains to be determined.  
 
RAD52 has a number of roles in DNA repair including playing a key role in the rescue of stalled 
replication forks29.  Silencing of RAD52 is synthetic lethal with mutations in BRCA1, BRCA2 or 
PALB230 31,32. Although the exact mechanisms responsible for these synthetic lethal interactions 
remain to be fully understood, these observations have led to efforts to develop small molecule 
RAD52 inhibitors33. MUS81 endonuclease activity also appears to be required for replication 
fork progression in BRCA2-mutant cells. It has been proposed that inhibitors of MUS81 
nuclease activity may have utility for the treatment of BRCA2-deficient cancers34. 
 
Patel and colleagues have shown that cells deficient in Fanconi Anemia (FANC) genes are 
sensitive to endogenous acetaldehyde produced as a consequence of cellular metabolism35 . 
Recently, it has also been shown that defects in either BRCA1 or BRCA2 also sensitise cells to 
acetaldehyde. Endogenous acetaldehyde is removed through the action of Aldehyde 
Dehydrogenases (ALDHs); Tacconi et al. found that the drug disulfiram, an ALDH2 inhibitor, 
selectively inhibits the proliferation of BRCA1 and BRCA2 deficient cells36. Given that disulfiram 
in the form of Antabuse is in wide usage for the treatment of alcoholism, it seems possible that 
this work could be rapidly translated clinically.   
 
Targeting other DDR defects in tumors. The success in exploiting synthetic lethality using 
PARPi has renewed interest in targeting other components of the DDR as synthetic lethal 
approaches to treating cancer. One of the most promising targets in this regard is ATR (Ataxia 
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Telangectasia Related), a protein kinase which is activated by RPA binding to single stranded 
(ss)DNA at stalled replication forks. CHK1, which is a critical regulator of the G2/M and intra-S cell 
cycle checkpoints, is an important substrate of ATR. A related DDR kinase, ATM ((Ataxia 
Telangectasia Mutated) is also being targeted by drugs. Histone H2AX is a substrate of ATM and 
ATM phosphorylation of H2AX within histones flanking DNA double strand breaks facilitates the 
recruitment of additional DDR components.  Another important substrate of ATM is CHK2 which 
has a role in the G1/S cell cycle checkpoint. Potent inhibitors of ATR kinase activity in clinical 
development include VX-970 (Vertex Pharmaceuticals; now Merck KGA) and AZD6738 
(AstraZeneca). A phase I trial of the ATM inhibitor AZD0156 (AstraZeneca) is ongoing 
(NCT02588105). These drugs are being investigated as single agents as well as in combination 
with chemotherapy, radiation, PARPi and immunotherapy. Biomarkers of response to ATR 
inhibitors are currently being explored and include ATM deficiency, DDR pathway mutations as 
well as genomic alterations that induce replicative stress including p5337,38. Mutation of the 
chromatin remodelling component, ARID1A, has also been suggested to mediate ATR inhibitor 
sensitivity39 (see below). Clinical data is thus far limited but an anecdotal complete clinical 
response to an ATR inhibitor has been observed in a patient with metastatic ATM-deficient 
colorectal40. A number of other synthetic lethal interactions are being explored in the DDR space. 
One well validated such interaction is between RAD54B deficiency in colorectal cancer and 
silencing of the flap endonuclease FEN141.  
 
(ii) Chromatin remodelling and epigenetic regulation  
 
Mutations in genes that regulate chromatin structure and epigenetic regulation are present in up 
to 20% of all human malignancies42. Most commonly these mutations are in chromatin 
remodelling tumor suppressor genes but gain of function mutations also occur. For example, the 
SWI/SNF BAF and PBAF chromatin remodelling complexes are composed of more than a dozen 
protein subunits, many of which are well-established tumour suppressor proteins. These 
SWI/SNF complexes mediate the mobilisation of nucleosomes along DNA, allowing the regulation 
of gene expression and facilitating DNA replication and repair processes. A number of synthetic 
lethal interactions have now been described for deficiencies in SWI/SNF-complex components, 
some of which are being tested in clinical trials42. 
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In what may be a general phenomenon related to protein complexes and synthetic lethality (see 
later), loss of some SWI/SNF subunits is synthetic lethal with depletion of other SWI/SNF 
subunits. For example, SNF5 (SMARCB1) and the ATPase BRG1 are synthetic lethal; the 
inactivation of Brg1 abrogates tumorigenesis in Snf5 deficient mice. Human SWI/SNF complexes 
contain one of two core ATPases, BRG1 (SMARCA4) and BRM (SMARCA2) which are mutually 
exclusive. BRG1 is often mutated in cancers, including those of the lung, pancreas and brain. 
Several groups showed that BRG1 and BRM are synthetic lethal, both in cell lines and in vivo, 
due to absence of ATPase activity in the SWI/SNF complex43-46. This is one such example of 
defects in paralogs causing synthetic lethal (see later and Figure 1). 
 
SNF5 is a component of the SWI/SNF complex which is frequently mutated in childhood malignant 
rhabdoid tumors as well as other cancers. One such synthetic lethal interaction showing particular 
promise is between SNF5 deficiency and inhibition of the polycomb complex histone 
methyltransferase EZH2. EZH2 induces epigenetic silencing of the CDKN2A tumor suppressor 
gene when SNF5 is deficient. Upon inhibition of EZH2, CDKN2A is reactivated suppressing 
proliferation. Whether EZH2 inhibition shows clinical efficacy in SNF-deficient cancers is now 
being tested in clinical trials. EZH2 inhibition47,48 also shows synthetic lethal with SWI/SNF 
components ARID1A, BRG1 (SMARCA4) and PBRM149. 
 
Deleterious mutations in ARID1A, which encodes a DNA binding subunit of the BAF complex, are 
present in multiple human cancers including of the endometrium (21%50), liver (10%51) stomach 
(21%52) and other sites. Over half of the hard to treat ovarian clear cell carcinomas carry a 
mutation in ARID1A. Because of the prevalence of ARID1A mutations, a number of investigators 
have identified genetic and chemical synthetic lethal partners of ARID1A. Project Achilles 
(described below) identified defects in the paralogous DNA binding BAF subunit, ARID1B, as 
being synthetic lethal with ARID1A defects; absence of both paralogs leads to destabilisation of 
the SWI/SNF complex53 (Figure 1). ARID1A has been suggested to facilitate maintenance of 
genome stability through a role in the repair of DNA breaks by homologous recombination repair. 
As such ARID1A-deficient cells have been reported as being modestly sensitive to PARPi 
treatment in vitro54,55. In addition, ARID1A deficiency has been shown to be synthetic lethal with 
inhibition of PI3K/AKT56 and also to result in sensitivity to the kinase inhibitor dasatinib57. Recently, 
a profound sensitivity of ARID1A deficient cells to ATR inhibitors has been described55.  
Mechanistically, ARID1A-deficiency results in DNA processing defects during mitosis, which 
cause an increased reliance upon ATR function. Clinical trials to test this hypothesis are 
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underway. Models of ovarian clear cell carcinoma with defects in ARID1A have also been shown 
to be reliant upon the histone deacetylase protein, HDAC658. Loss of the repressive effect of 
ARID1A on HDAC6 transcription allows HDAC6 to deacetylate p53, reducing its pro-apoptotic 
function, an effect that is apparent in pre-clinical models using the clinical HDAC inhibitor, 
ACY121558.  
 
Synthetic lethal relationships have been described in epigenetic regulatory pathways beyond 
SWI/SNF. SETD2, encodes a histone methyltransferase that catalyses the production of 
Histone H3K36me3, which is associated with heterochromatin59. Loss of function mutations in 
SETD2 are common in clear cell renal carcinomas. Inhibition of the cell cycle checkpoint kinase 
WEE1 has been shown to be synthetic lethal with SETD2 mutation. WEE1 inhibition in SETD2 
mutant cells appears to result in reduced levels of the ribonucleotide reductase subunit RRM2 
reduction leading to dNTP depletion and S-phase arrest60.  
 
(iii) Signal Transduction Pathways  
 
Aberrations in cell signalling occur frequently in human cancers. In particular, the Ras family of 
oncogenes (Kras, Nras, and Hras) are the most common genetic drivers, being activated by 
mutation in approximately 20% of cancers. Despite considerable efforts over many decades, 
direct inhibitors of Ras are not yet available clinically, although there are some signs that novel 
approaches to drug discovery may be more fruitful in this regard (e.g.61). Because of this, indirect 
approaches such as the use of synthetic lethality have been explored. Both mechanism driven 
and screening approaches have been employed. Although the delineation of robust Ras synthetic 
lethal effects has not been straightforward, a number of lessons have been learned that may allow 
a path towards identifying clinically actionable effects. Furthermore, the considerable effort 
expended in searching for Ras synthetic lethal effects has established principles that may assist 
the discovery of robust synthetic lethal effects in other systems.  
 
Many mutant Ras synthetic lethal screens have been published. For example, an early short 
hairpin RNA (shRNA) screen of the kinome identified the TANK-binding kinase 1 (TBK1) as a 
Kras synthetic lethal target62. This appeared to operate via TBK1 activation of the NF-kB pathway, 
a requirement for survival of Kras-mutant driven lung cancer cells. Another screen identified the 
kinase STK33 as being a synthetic lethal partner of mutant Ras. However, subsequent attempts 
to validate STK33 have led some to conclude that the synthetic lethal interaction was not widely 
applicable and might be private to specific model systems63 64. In general, there has been little 
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overlap in the synthetic lethal effects identified in different synthetic lethal screens. There are a 
number of possible explanations for this that have been thoughtfully discussed by Downward65. 
These include the heterogeneity of the cell systems (genetic background, cellular state, histology) 
used, whether the effects operate in 2D tissue culture rather than in vivo; differences between 
individual RAS mutations and methodological differences in the statistical analysis of high 
throughput screens. The general principle established in this work however, is that many of the 
synthetic lethal effects identified in individual Kras mutant model systems might be relatively 
private to these systems; these private events are readily reversed when assessed in a different 
Kras mutant context (i.e. a different model system), and are thus unlikely to be robust in the face 
of the considerable molecular and phenotypic heterogeneity seen in human cancers3.  
 
Recently, Sabatini and colleagues66 have performed genome-wide CRISPR/Cas9 screens in 14 
Acute Myeloid Leukemia (AML) cell lines. The comparison of six KRAS/NRAS mutant lines with 
six wild-type lines allowed the identification of a small number of synthetic lethal genes which are 
involved in RAS processing (e.g. RCEI and ICMT) and MAPK signalling (e.g. RAF1, SHOC2). 
These same synthetic lethal effects were reconfirmed in isogenic matched Ba/F3 cells with a 
NRAS mutation. These results suggest that at least in AML, there are relatively few RAS synthetic 
lethal partners and that these are restricted to RAS processing or MAPK signalling. That only a 
few bona fide RAS synthetic lethal effects were discovered and that these can be histology-
specific, may go some way to explaining why large-scale screens of heterogeneous cell lines from 
multiple different cancer types, have failed to identify common RAS synthetic lethal genes.  
 
A number of other Ras synthetic lethal interactions (reviewed recently67) have been described 
with genes from the DDR68 (for example, ATR69), cell cycle (for example, CHK1)70,71, the 
proteasome and proteolytic stress (e.g. through HSP90 inhibition)72 as well as with transcription 
factors, such as GATA273,74. It remains to be seen whether these will prove to have clinical utility.  
 
Synthetic lethal approaches have been used to investigate signal transduction genes other than 
RAS. For example, using a mutual exclusivity approach DePinho and colleagues75 discovered 
chromatin helicase DNA-binding factor CHD1 depletion as being potentially selectively lethal to 
PTEN-deficient prostate and breast cancers. PTEN normally promotes CHD1 degradation via the 
β-TrCP-mediated ubiquitination–proteasome pathway. The absence of PTEN results in 
stabilization of CHD1, leading to activation of pro-tumorigenic TNF–NF-κB signalling.  
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(iv) Metabolism  
 
Somatic mutations in cancer have been identified in genes involved in energy metabolism opening 
up the possibility of targeting the rewired metabolic state via synthetic lethal approaches. FH 
(Fumarate hydrolase) germline mutations are associated with hereditary leiomyomatosis and 
renal cell carcinoma. FH deficiency leads to the accumulation of fumarate, which activates 
hypoxia-inducible factors (HIFs) in the absence of hypoxia. However, it was unclear how cells 
survive in the absence of functional tricarboxylic acid (TCA or Krebs’) cycle. Frezza et al.76 used 
computational modelling and metabolomic profiling to identify a metabolic alteration that occurs 
as a consequence of FH deficiency. Truncation of the TCA cycle resulted in movement of 
glutamine-derived carbon atoms into the heme biosynthesis and degradation pathway. As a 
result, FH1-deficient cells can use accumulated TCA cycle metabolites to allow sufficient 
mitochondrial NADH production. However, as a result, silencing of Haem Oxygenase 1, or 
inhibition of the enzyme with Zinc protoporphyrin, resulted in selective growth impairment of Fh1-
deficient cells compared to control cells.  
 
Mutations in the key respiratory enzyme Succinate Dehydrogenase (SDH complex) are present 
in the rare tumors pheochromocytoma, paraganglioma and gastro-intestinal stromal tumors77. 
Mechanistic analysis suggests that mutations in SDH complex genes result in a truncated TCA 
cycle which causes a defect in aspartate production which is normally required for nucleotide 
biosynthesis. As an alternative, SDH mutant tumors use pyruvate and pyruvate carboxylase to 
sustain aspartate biosynthesis. As a consequence, SDH mutant tumors are hypersensitive to 
pyruvate carboxylase silencing, while non-transformed cells are able to use the canonical 
pathway for aspartate biosynthesis78. 
Gain of function mutations in two related Isocitrate Dehydrogenases (IDH1 and IDH2) occur in 
gliomas and Acute Myeloid Leukemias (AML)79. Mutations in these enzymes lead to the 
neomorphic production of the oncometabolite (R)-2-hydroxyglutarate (2-HG). Inhibitors of mutant 
IDH1/2 have been developed and have shown efficacy in the clinic 79. In addition, studies have 
been performed investigating synthetic lethal approaches to treating IDH1/2 mutant cancers. 
IDH1/2 mutant cells are sensitive to PARPi80; 2-Hydroxyglutarate produced by neomorphic IDH 
mutations appears to suppress DNA repair by HR and hence sensitises cells to PARPi. Moreover, 
synthetic lethal relationships to IDH1/2 with the apoptotic proteins Bcl2 in AML and BclXL in 
glioma have been described 81,82. 
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The von Hippel–Lindau tumor suppressor gene (VHL), is commonly mutated or promoter 
hypermethylated in clear cell renal cell carcinoma83. VHL encodes an oxygen-dependent ubiquitin 
ligase that regulates the degradation of the hypoxia-inducible factor 1D (HIFD) transcription 
factor. In the presence of oxygen, HIF1D is hydroxylated on proline residues by EglN prolyl 
hydroxylases and subsequently ubiquitinated by VHL. Loss of VHL activity results in dysregulated 
HIF1D  activity which drives the development of renal cell carcinoma83. A number of synthetic 
lethal interactions with VHL loss have been described. An siRNA screen identified the histone 
methyltransferase EZH1 as a potential synthetic lethal partner of VHL loss; this interaction was 
validated by pharmacological inhibition of EZH1. In addition, chemical screens identified inhibitors 
of autophagy, GLUT1 and Rho-associated kinase 1 as potential synthetic lethal therapies for VHL-
related cancers84-86. 
When tumor suppressor genes are deleted in cancer other putative passenger genes may also 
be co-deleted which result in potential vulnerabilities; the loss of such genes has been termed 
collateral lethality/sensitivity9,10. Three groups discovered that deletion of the MTAP gene confers 
enhanced dependence on the PRMT5 arginine methyltransferase87-89. MTAP is adjacent in the 
genome to the tumor suppressor gene CDKN2A (p16). CDKN2A is commonly homozygously 
deleted in cancer and MTAP is frequently co-deleted with CDKN2A (~15% of all cancers and 
>50% of glioblastoma multiforme). MTAP encodes an enzyme which cleaves 
methylthioadenosine (MTA) generating precursors for methionine and adenine synthesis. The 
absence of MTAP leads to an accumulation of MTA in the cell which leads to partial inhibition of 
PRMT5. As a consequence, cancers with loss of MTAP are more sensitive to inhibition of 
PRMT587-89 and number of companies are now developing PRMT5 inhibitors.  
 
ENO1, encoding the important glycolytic enzyme, enolase, is often homozygously deleted at 
chromosome 1p36, alongside multiple tumor suppressor genes. In the absence of enolase, cells 
cannot produce ATP because of defective glycolysis. The fact that such a deletion is not lethal to 
the cell may be due to the existence of a paralog of ENO1 called ENO2. DePinho and colleagues10 
showed that shRNA depletion or chemical inhibition of ENO2 was selectively lethal to glioma cells 
carrying an ENO1 deletion suggesting a targetable. synthetic lethal-type interaction. Similarly, 
genomic deletion of Malic enzyme 2 in pancreas cancer also confers collateral lethal dependency 
on Malic enzyme 390.  
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(v) Synthetic lethal interactions with other major cancer-related genes  
 
Despite the considerable success in developing targeted therapy, for mutated kinases in cancer 
there has been little progress in developing therapies for many of the major genes that are 
mutated or overexpressed in cancer such as Myc, Rb and P53. These remain significant targets 
for synthetic lethal approaches.  
 
Myc: The Myc oncogene is dysregulated in a significant proportion of human cancers. There are 
three Myc family members c-, L-, and N-Myc, all of which have been linked to tumor pathogenesis 
and progression. The Myc proteins are transcription factors that regulate multiple cellular 
functions including proliferation, growth and metabolism91. There is considerable evidence that 
Myc is potentially an extremely important therapeutic target. However, as a transcription factor, 
Myc has proved thus far impossible to target directly. Therefore, a number of attempts have been 
made to target Myc indirectly using synthetic lethal approaches92,93.  
 
Given the role of Myc proteins in cellular proliferation, considerable attention has been paid to 
synthetic lethal interactions with cell cycle regulatory components; for example, small molecule 
inhibition of CDK2 is synthetic lethal with Myc overexpression94.  In addition, CDK1 inhibition using 
the inhibitor purvalanol A induces apoptosis in cells overexpressing Myc, prolongs survival in 
mouse myc–driven lymphoma models95. An additional link to apoptosis was provided by the 
finding that TRAIL and DR5-agonists were synthetic lethal with dysregulated Myc96. 
 
A number of other Myc synthetic lethal interactions have been described such as SAE1/2, an 
enzyme involved in SUMOylation which was identiﬁed in a MYC synthetic lethal genome-wide 
RNAi screen. In Myc driven cells, depletion of SAE1/2 caused mitotic catastrophe in Myc 
hyperactive cells97. PIM1 kinase was identified in MYC synthetic lethal kinome RNAi screen and 
appears to act inhibiting the oncogenic transcriptional activity of MYC and restoring the activity 
of the cell cycle inhibitor, p2798. As PIM1 kinase inhibitors are available, this observation could 
be readily tested clinically. Other Myc synthetic lethal interactions with genes involved in 
pathways such as transcription99, RNA splicing100 and metabolism 101 amongst others.  
 
Rb: RB1 (Rb) is commonly lost by mutation or transcriptional silencing in the childhood eye 
cancer, retinoblastoma, breast cancer, prostate, lung cancer, sarcomas, and glioblastoma 102. The 
canonical role of Rb is in cell-cycle control and proliferation103,104, where Rb, together with D-type 
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Cyclins, Cyclin-dependant kinases and inhibitors, Rb pocket proteins and the E2F family of 
transcription factors, control the progression of cells through the G1 restriction checkpoint. A 
number of chemogenetic Rb synthetic lethal interactions have been identified, including 
topoisomerase poisons, such as etoposide; Rb is thought to mediate the processing and repair 
of DNA damage caused by these agents by binding both Type II topoisomerases and BRCA1 and 
recruiting them to the site of DNA damage105. A number of synthetic lethal gene targets associated 
with Rb defects have also been identified. Simultaneous inactivation of Rb and the Tsc2 in 
Drosophila causes synthetic lethality, an effect conserved in human tumour cells106. TSC2, 
together with TSC1, forms a heterodimer that controls mTOR (mechanistic target of rapamycin) 
signalling via TORC1; the synthetic lethal between Rb and TSC2 appears to be dependent upon 
dysregulation of the TORC1 effector S6-kinase and the Rb-dependent transcription factor 
E2F1106. Similarly, upregulated Wnt signalling, caused for example by loss of APC tumour 
suppressor gene function, also causes Rb synthetic lethal via TORC1 dysregulation107. Large 
scale shRNA screens in human tumour cell lines demonstrated the dependency of Rb defective 
tumour cells upon E2F-family transcription factors including E2F3108,109. This might relate to the 
roles that some E2F transcription factors have in minimising replication stress and DNA damage 
in cells with Rb defects110,111. Finally, combined defects in Rb and p53 impart a dependency upon 
the  RNase III enzyme Dicer1 perhaps related to the oncogenic miR-17-92 cluster112. 
 
p53: p53 is one the most commonly mutated tumor suppressor genes; p53 itself or regulators of 
p53 activity are dysfunctional in most human cancers113. The p53 gene encodes a transcription 
factor activated by multiple cellular stresses that is a major regulator of DNA repair, cell cycle 
arrest apoptosis and metabolism114. Moreover, loss of p53 function affects the response to many 
cytotoxic chemotherapies and is associated with poor survival. These observations have led to 
many efforts to restore p53 function or to inhibit aberrant p53 signalling in cancers. In addition, 
multiple synthetic lethal approaches to targeting p53 mutant tumors have been discovered in 
many cellular pathways including the DDR (see section 2i), metabolism and cell cycle regulation; 
the area of synthetic lethal interactions with P53 has recently been extensively reviewed115.  
 
3. Approaches to discover and validate synthetic lethal and CS interactions  
 
Cancer derived cell lines cultured in vitro on plastic have been the mainstay of experimental 
systems to define new synthetic lethal relationships. For example, genome-wide RNA interference 
screens in large panels of cancer derived cell lines, where the dependency upon multiple distinct 
Synthetic lethality: Beyond PARPi/BRCA   14
genes is established, has allowed a first draft of synthetic lethal effects that operate in cancer 
cells to be delineated 108,109,116-118. This large-scale mapping of synthetic lethal relationships in 
human cancer cells has also facilitated a more refined classification of synthetic lethal effects. For 
example, an analysis of synthetic lethal effects associated with 800 genes in 400 cancer cell lines, 
identified three broad, and sometimes overlapping, classes of synthetic lethal effect109: (a) 
pathway synthetic lethal effects, where synthetic lethal partners act in either parallel pathways or 
within the same pathway to modulate a process that is essential in tumor cells; an example is the 
synthetic lethal between the tumor suppressor APC and E-catenin, both of which modulate 
oncogenic Wnt signalling; (b) paralog effects, where synthetic lethal partners are paralogs that 
still retain at least one overlapping function that is essential in tumor cells, e.g. the cyclin 
dependent kinases CDK4 and CDK6, or the SWI/SNF proteins ARID1A and ARID1B; and (c) 
collateral lethality effects, as described earlier. Similarly, other classifications of synthetic lethal 
have been proposed that include the overlapping concepts of protective essential genes7 and 
induced essential effects8, both of which describe the scenario where an alteration in one gene is 
deleterious unless mitigated by the activity of a second gene; inactivation of this second gene 
leads to synthetic lethality. This might be highly relevant in cancer, where driver alterations (e.g. 
oncogene activation or tumour suppressor gene loss) impart an eventual fitness advantage upon 
cells but might also cause deleterious effects that if not kept in check, could result in cell death. 
For example, replication fork stress caused by oncogenes may be tumor promoting (for example, 
by promoting DNA mutations) but might also impart a heightened requirement for proteins, such 
as ATR, that prevent the deleterious effects of excessive fork stress, an effect that could be 
exploited with clinical ATR inhibitors. Defining the different modes by which synthetic lethal effects 
operate could, in principle, allow novel synthetic lethal interactions to be predicted, rather than 
identified empirically. 
 
Other approaches, both computational and experimental, are also augmenting the search for new 
synthetic lethal interactions. For example, the delineation of genome-wide protein–protein 
interaction (PPI) maps in model organisms has led to the observation that essential proteins 
tend to have a higher number of interactions than those that are less essential7; in principle, 
applying a similar analysis to understand the interactome of synthetic lethal target proteins 
could facilitate the prediction of new synthetic lethal effects. Furthermore, a recent analysis of 
tumour profiling datasets suggests that loss of individual protein complex components in 
tumors (for example via gene deletion), often results in a partial or complete loss of other parts 
of the protein complex from the tumour119. In some cases, further inhibition of these collaterally-
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lost complex subunits results in synthetic lethal119, suggesting that an in silico analysis of tumor 
proteomes could be used to predict synthetic lethal effects. 
 
At the experimental level, advances in gene perturbation technologies will likely enhance the 
ability to empirically identify and validate synthetic lethal interactions. Whilst much of the focus 
over the past decade has been on exploiting RNA interference, transposon mutagenesis and 
chemical mutagenesis of genomes to identify synthetic lethal effects, gene editing by 
CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats) approaches has 
gained widespread application in this regard. More recently, modifications of the CRISPR system 
have become available so that genes can be transcriptionally silenced (CRISPRi) or activated 
(CRISPRa)120. These methods can be used in combination to define genetic interactions on a 
large scale. Moreover, CRISPRi has been combined with single cell sequencing in a technique 
called PERTURB-Seq121 to uncover new components of pathways as well as the targets of drugs. 
CRISPR systems adapted to mutate or alter the expression of more than one gene are ideally 
suited to the definition of genetic interaction networks and may allow the discovery of higher order 
interactions.  
 
4.Conclusions and Future Prospects  
 
The success of the discovery and development of parpi as an synthetic lethal therapy for BRCA1 
and BRCA2-mutated cancers has driven research into better understanding of genetic 
interactions between cancer genes and potential therapeutic targets. as well as hypothesis-driven 
approaches, large scale experimental and computational methodologies are being used to 
discover cancer specific synthetic lethal interactions at an unprecedented rate. however, parpi 
remain the only fda approved synthetic lethal therapy and many of the major genetically altered 
genes in cancer such as p53 and rb remain undrugged. it is important, therefore, to consider what 
will be required to discover and develop additional such therapies.  
 
In considering whether a given synthetic lethal interaction might eventually deliver clinical benefit 
it is critical to take the magnitude of the synthetic lethal effect into account. in terms of the size of 
the synthetic lethal effect the parpi/brca interaction is substantial being >100-fold depending on 
the system. Some of the synthetic lethal interactions described thus far may be statistically 
significant and even biologically meaningful but are too small to translate into efficacy in the clinic.  
Discovery and validation strategies should emphasise substantial synthetic lethal effects. Likely 
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better screening technologies linked to improved computational analysis will yield more suitable 
synthetic lethal interactions. 
 
Some synthetic lethal interactions, as exemplified by many of those in the RAS field, are histology, 
cell type or genetic background dependent ie private. These “soft” synthetic lethal effect need a 
distinct development strategy compared to “hard” effects such as the PARPi/BRCA interaction 
which are more resistant to this heterogeneity. The choice of systems for discovery and 
development is also important. For many tumor suppressor genes there are insufficient numbers 
of cell lines available that carry specific genetic lesions especially when heterogeneity is taken 
into account. This limits evaluation of histology dependent effects. 
 
One clear challenge to the field is how methods might be developed that allow robust synthetic 
lethal effects (i.e. those that are relatively resilient to other molecular changes or plasticity) to be 
predicted from first principles; at present the robustness of synthetic lethal effects is critical if 
effective treatments are to be developed but is still largely determined by empirical means (e.g. 
assessment in multiple model systems) which are often time consuming and expensive. it seems 
reasonable to think that the ability to discriminate robust synthetic lethal effects from those that 
are less robust might emerge from learning the characteristics of known, robust, synthetic lethals. 
some of these characteristics might emerge from the further analysis of existing synthetic lethal 
screens (e.g. large-scale shrna or crispr-cas9 screens in cancer cell lines) or even by assessing 
whether some of the predictable characteristics of essential genes in model organisms7 apply to 
cancer cells. moreover, screens and subsequent validation in more biologically appropriate 
systems such as 3d organoid culture or in vivo in mice might yield more robust synthetic lethal 
effects.  
 
An underexploited aspect of the synthetic lethal principle is the simultaneous exploitation of 
multiple distinct synthetic lethal effects to uncover novel combination therapies. Most solid 
tumours are driven by a number of truncal driver mutations, offering the possibility of rationally 
designing combination therapies that target multiple distinct driver effects at the same time. For 
example, the co-occurrence of APC tumour suppressor mutations with KRAS mutations in some 
tumours might predict response to Wnt pathway inhibitors that are synthetic lethal with the APC 
defect as well as MAP-kinase signal transduction inhibitors that target the KRAS addiction. 
Likewise, in animal models of triple negative breast cancer that possess both Brca1 gene defects 
and also Fgfr2-oncogenic fusions, the combination of a PARP inhibitor, targeting the Brca1 defect, 
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and a FGFR inhibitor, targeting the Fgfr2 fusion, is more effective than either agent alone122. Such 
combination synthetic lethal approaches are not conceptually complex but might deliver 
comparable, if not better, results that combination therapies that act synergistically on a single 
driver mutation, so long as the two drugs used have distinct mechanisms of action and are 
therefore less likely to be impacted by singular mechanisms of drug resistance. Already there is 
some understanding that many of the drug combination approaches that have empirically been 
found to be effective in treating cancer work by combining distinct mechanisms of action123; 
perhaps the task ahead is to rationally design new approaches that exploit this effect, by first 
identifying synthetic lethal interactions with individual driver gene defects.  
 
A separate extension of the synthetic lethal principle might be to identify higher order synthetic 
lethal effects. Rather than single cancer driver genes being synthetic lethal with inhibition of a 
target (e.g. inhibition of A is synthetic lethal with a defect in B), inhibition of a combination of 
targets is required to elicit a synthetic lethal effect (e.g. inhibition of A, plus inhibition of B, is 
synthetic lethal with a defect in C). There seems no a priori reason why such higher order synthetic 
lethal interactions might not be as prevalent as classical synthetic lethal effects. Indeed, many of 
the proposed drug combination strategies in cancer might already exploit this concept, albeit not 
by design; such higher order effects probably work by simultaneously targeting a driver gene 
effect by synthetic lethality as well as any synthetic rescue effect that would otherwise reverse 
the primary synthetic lethality. 
 
In conclusion, therefore, the approval of PARPi has driven excitement about the prospects of 
further clinically effect synthetic lethal therapies. A number of already discovered additional 
synthetic lethal interactions are showing promise and with the advent of powerful new 
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Table 1. PARP Inhibitors that have received FDA regulatory approval for clinical use 
 
Agent Company FDA Approval(s) 
Olaparib (Lynparza) AstraZeneca (formerly KuDOS) 
Ovarian Cancer: for the 
maintenance treatment of 
adult patients with recurrent 
epithelial ovarian, fallopian 
tube or primary peritoneal 
cancer, who are in a 
complete or partial 
response to platinum-
based chemotherapy.  
Ovarian Cancer: for the 
treatment of adult patients 
with deleterious or 
suspected deleterious 
germline BRCA-mutated 
advanced ovarian cancer 
who have been treated with 
three or more prior lines of 
chemotherapy. Patients are 
selected for therapy based 
on an FDA-approved 
companion diagnostic that 
identifies deleterious 
germline BRCA1 or BRCA2 
gene mutations (Myraid, 
BRACAnalysis CDx test). 
Breast cancer: in patients 
with deleterious or 
suspected deleterious 
germline BRCA-mutated, 
human epidermal growth 
factor receptor 2 (HER2)-
negative metastatic breast 
cancer who have been 
treated with chemotherapy 
in the neoadjuvant, 
adjuvant or metastatic 
setting. Patients with 
hormone receptor (HR) 
positive breast cancer 
should have been treated 
with a prior endocrine 
therapy or be considered 
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inappropriate for endocrine 
therapy. Patients are 
selected for therapy based 
on an FDA-approved 
companion diagnostic that 
identifies deleterious 
germline BRCA1 or BRCA2 
gene mutations (Myraid, 
BRACAnalysis CDx test). 
 
Rucaparib (Rubraca) Clovis (formerly Pfizer) 
Ovarian Cancer: 
monotherapy for the 
treatment of patients with 
deleterious BRCA mutation 
(germline and/or somatic) 
associated advanced 
ovarian cancer who have 
been treated with two or 
more chemotherapies. 
Patients are selected for 
therapy based on an FDA-
approved companion 
diagnostic that identifies 
deleterious germline 





Niraparib (Zejula) Tesaro (formerly Merck) 
Ovarian Cancer: for the 
maintenance treatment of 
adult patients with recurrent 
epithelial ovarian, fallopian 
tube, or primary peritoneal 
cancer who are in a 
complete or partial 
response to platinum-
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Figure Legends 
 
Fig 1. Pathway based synthetic lethality – synthetic lethality between parallel pathways acting on 
a process that is essential in tumor cells. An example of the synthetic lethal interaction between 
BRCA1 and POLQ is shown (refs 27,28).  
 
Fig 2. Pathway based synthetic lethal - synthetic lethality between multiple components in a 
pathway that is essential in tumor cells. Interactions in the Wnt pathway are shown.  
 
Fig. 3. Paralog based synthetic lethal – synthetic lethality between two paralogs. An example of 
the synthetic lethal interaction between SWI/SNF components ARID1A and ARID1B are shown 
(ref 53). 
 
Fig. 4. Collateral synthetic lethal via loss of genetic material– the collateral loss of genetic material 
(deleted material indicated by blue shading) linked to a tumour suppressor gene causes a 
haploinsufficiency effect. In this example genetic material carrying the MTAP gene is lost when 
the cancer driver CDKN2A is deleted. Loss of MTAP is synthetic lethal with PRMT5 inhibition (refs 
87-89). 
 
Fig. 5. Collateral synthetic lethal via complex collapse – loss of one protein subunit causes 
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Fig. 3. Paralog based synthetic lethal – synthetic lethality 
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interaction between SWI/SNF components ARID1A and 





Fig. 4. Collateral synthetic lethal via loss of genetic 
material– the collateral loss of genetic material (deleted 
material indicated by blue shading) linked to a tumour
suppressor gene causes a haploinsufficiency effect. In this 
example genetic material carrying the MTAP gene is lost 
when the cancer driver CDKN2A is deleted. Loss of MTAP 
is synthetic lethal with PRMT5 inhibition (refs 87-89).
Deleted Tumor suppressor gene eg CDKN2A
Co-deleted gene eg MTAP = synthetic lethal with 
PRMT5
Fig. 5. Collateral synthetic lethal via complex collapse –
loss of one protein subunit causes complex collapse and 
new vulnerability (ref 119).
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